Diagnostic and prognostic utility of (18)F-FDG PET/CT in recurrent salivary gland cancers Journal Article
| Authors: | Nakajima, R.; Patel, S. G.; Katabi, N.; Flukes, S.; Mauguen, A.; Ganly, I.; Schöder, H. |
| Article Title: | Diagnostic and prognostic utility of (18)F-FDG PET/CT in recurrent salivary gland cancers |
| Abstract: | OBJECTIVE. The role of 18F-FDG PET/CT in the evaluation of recurrent salivary gland tumors remains poorly defined. We investigated the diagnostic and prognostic utility of PET in this setting. MATERIALS AND METHODS. A total of 146 patients with recurrent salivary gland cancer were treated at our institution between January 2002 and December 2015. Patients who underwent FDG PET/CT and conventional imaging (CT or MRI) within 3 months of recurrence (n = 78) were included in this retrospective analysis. On FDG PET/CT, we measured the SUVmax, total body metabolic tumor volume of all lesions, and total lesion glycolysis of all lesions to determine the intensity and extent of FDG-avid disease. We assessed the correlation of FDG PET/CT findings with clinicopathologic features, progression-free survival, and overall survival. RESULTS. FDG PET/CT was positive for recurrence in 74 of 78 patients (94.9%) and falsely negative in four patients (5.1%). In comparison with conventional imaging, FDG PET/CT performed for restaging detected additional recurrent lesions in 14 patients (17.9%). The median SUVmax was 7.4, the median total body metabolic tumor volume was 30.1 cm3, and median total lesion glycolysis was 97.3 g/mL × cm3. Sixty-six patients had progressive disease, and 54 died. Univariate and multivariate Cox hazards analysis identified pathologic risk group (p = .04), total body metabolic tumor volume (p < .001), and total lesion glycolysis (p < .001) as independent prognostic factors for progression-free survival and identified age (p = .05), total body metabolic tumor volume (p < .001), and total lesion glycolysis (p < .001) as independent prognostic factors for overall survival. CONCLUSION. In patients with recurrent salivary gland cancer, FDG PET/CT is useful as a single test for defining the extent of disease and providing prognostic information, which may help in selecting appropriate treatment strategies. © American Roentgen Ray Society |
| Keywords: | fdg pet/ct; metabolic tumor volume; prognosis; recurrent salivary gland cancer |
| Journal Title: | American Journal of Roentgenology |
| Volume: | 216 |
| Issue: | 5 |
| ISSN: | 0361-803X |
| Publisher: | American Roentgen Ray Society |
| Date Published: | 2021-05-01 |
| Start Page: | 1344 |
| End Page: | 1356 |
| Language: | English |
| DOI: | 10.2214/ajr.20.23259 |
| PUBMED: | 33826358 |
| PROVIDER: | scopus |
| PMCID: | PMC9215107 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 June 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work